Table 1.
Patient characteristics (n = 38, time period 2007–2020)
| Parameter | n | % |
|---|---|---|
| Female sex | 20 | 53 |
| Male sex | 18 | 47 |
| No extracranial metastases | 10 | 26 |
| Liver metastases | 9 | 24 |
| Bone metastases | 12 | 32 |
| Only one extracranial distant site affected | 7 | 18 |
| Two such organs affected, e.g., bone + liver | 13 | 34 |
| Three or more organs affected | 8 | 21 |
| No brain radiotherapy at all | 15 | 39 |
| Karnofsky performance status 90–100 | 7 | 18 |
| Karnofsky performance status 70–80 | 27 | 71 |
| Karnofsky performance status < 70 | 4 | 11 |
| Whole-brain radiotherapy* | 19 | 50 |
| Higher dose radiotherapy | 4 | 11 |
| Single brain metastasis | 10 | 26 |
| Median number of brain metastases, range | 3 | 1–50 |
| Median size of the largest lesion, range (mm) | 10 | 3–30 |
| Median age, range (years) | 68.5 | 46–82 |
| Median LabBM score, range (points) | 1.5 | 0–3 |
*18 patients had received 30 Gy in 10 fractions of 3 Gy and one 25 Gy in 10 fractions of 2.5 Gy (higher dose means stereotactic radiotherapy without whole-brain radiotherapy (n = 2) or simultaneous integrated boost whole-brain radiotherapy (n = 2))